NL-OMON37300
尚未招募
不适用
ongitudinal analysis of lung cancer-specific immunity in stage III and IV non-small cell lung cancer patients - Longitudinal analysis of non-small cell lung cancer-specific immunity
Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 50 人待定
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- non-small cell lung cancer
- 发起方
- Antoni van Leeuwenhoek Ziekenhuis
- 入组人数
- 50
- 状态
- 尚未招募
- 最后更新
- 去年
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Histologically or cytologically proven irresectable stage III or IV non\-small cell lung cancer
- •Age above 18 years
- •Performance score: WHO 0, 1 or 2 at the time of study entry
- •Written informed consent
- •Specific inclusion criteria for tissue biopsies:
- •\- Only target lesion with limited biopsy\-procedure related complication risk will be sampled; For instance easily accessible peripheral lymph nodes, subcutaneous, pleural, liver metastastasis.
- •\- Other lesions will only be included if there is a clinical necessity for tissue analysis (e.g. molecular profiling, resection metastasis in case of oligometastastic disease).
- •\- Only non\-irradiated lesions will be sampled
排除标准
- •Severe anemia (Hb \< 6\.0 mmol/L)
- •Any bleeding disorder or anti\-coagulation therapy, that cannot be discontinued or corrected, that significantly increases the risk of a bleeding due to the biopsy.
结局指标
主要结局
未指定
相似试验
招募中
不适用
ongitudinal analysis of lung cancer-specific immunity in stage III and IV non-small cell lung cancer patients.NL-OMON25535Stichting Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek ZiekenhuisAmsterdam, The Netherlands50
已完成
不适用
Immune Response in Lung CancerLung CancerNCT01955343Lithuanian University of Health Sciences100
已完成
不适用
ongitudinal analysis of tumor-specific T-cel immunity in irresectable stage IIIc and stage IV melanoma patientsmelanomaskin cancer10040900NL-OMON36481eids Universitair Medisch Centrum50
已完成
不适用
Mechanisms of Immunosurveillance for Lung CancerLung CancerNCT01710319Washington University School of Medicine119
尚未招募
不适用
The Clinical Characteristics and Efficacy of Immunotherapy in First-line PD-L1-negative Advanced NSCLC PatientsNSCLCNCT06496009Shanghai Pulmonary Hospital, Shanghai, China845